SG11201807827VA - Process for the preparation of pegylated drug-linkers and intermediates thereof - Google Patents
Process for the preparation of pegylated drug-linkers and intermediates thereofInfo
- Publication number
- SG11201807827VA SG11201807827VA SG11201807827VA SG11201807827VA SG11201807827VA SG 11201807827V A SG11201807827V A SG 11201807827VA SG 11201807827V A SG11201807827V A SG 11201807827VA SG 11201807827V A SG11201807827V A SG 11201807827VA SG 11201807827V A SG11201807827V A SG 11201807827VA
- Authority
- SG
- Singapore
- Prior art keywords
- bothell
- washington
- international
- drive
- pct
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108010044540 auristatin Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662313460P | 2016-03-25 | 2016-03-25 | |
PCT/US2017/024148 WO2017165851A1 (en) | 2016-03-25 | 2017-03-24 | Process for the preparation of pegylated drug-linkers and intermediates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807827VA true SG11201807827VA (en) | 2018-10-30 |
Family
ID=59900804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807827VA SG11201807827VA (en) | 2016-03-25 | 2017-03-24 | Process for the preparation of pegylated drug-linkers and intermediates thereof |
Country Status (15)
Country | Link |
---|---|
US (2) | US11844839B2 (uk) |
EP (1) | EP3433278A4 (uk) |
JP (4) | JP7073266B2 (uk) |
KR (2) | KR102626498B1 (uk) |
CN (1) | CN109843919A (uk) |
AU (1) | AU2017237186B2 (uk) |
BR (1) | BR112018069273A2 (uk) |
CA (1) | CA3017527A1 (uk) |
EA (1) | EA201892040A1 (uk) |
IL (2) | IL261759B (uk) |
MA (1) | MA43835A (uk) |
SG (1) | SG11201807827VA (uk) |
TW (2) | TWI839055B (uk) |
UA (1) | UA125510C2 (uk) |
WO (1) | WO2017165851A1 (uk) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7261158B2 (ja) | 2016-10-19 | 2023-04-19 | インベンラ, インコーポレイテッド | 抗体構築物 |
KR20190074310A (ko) | 2016-11-08 | 2019-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
JP2020506716A (ja) | 2016-12-22 | 2020-03-05 | ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ | Cd43の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体 |
MX2019010769A (es) * | 2017-03-24 | 2019-12-11 | Seattle Genetics Inc | Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos. |
JP7364471B2 (ja) | 2017-05-18 | 2023-10-18 | レゲネロン ファーマシューティカルス,インコーポレーテッド | シクロデキストリンタンパク質薬物コンジュゲート |
IL313068A (en) * | 2017-11-07 | 2024-07-01 | Regeneron Pharma | Hydrophilic linkers for drug-antibody conjugates |
MA50259A1 (fr) | 2018-01-08 | 2021-07-29 | Regeneron Pharma | Stéroïdes et leurs conjugués-anticorps |
AU2019265703A1 (en) | 2018-05-09 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
US20210246187A1 (en) | 2018-06-05 | 2021-08-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
SG11202011915TA (en) | 2018-06-07 | 2020-12-30 | Seagen Inc | Camptothecin conjugates |
KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
CN118119409A (zh) | 2021-09-03 | 2024-05-31 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
US20240226313A1 (en) | 2022-11-17 | 2024-07-11 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
Family Cites Families (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8504461A1 (es) | 1982-04-12 | 1985-04-16 | Hybritech Inc | Un procedimiento para obtener un polidoma. |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5851527A (en) | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
FR2676058B1 (fr) | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US6569834B1 (en) | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
ATE282630T1 (de) | 1993-10-01 | 2004-12-15 | Teikoku Hormone Mfg Co Ltd | Dolastatin-derivate |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
DE19516717A1 (de) | 1995-05-06 | 1996-11-07 | Basf Ag | Verfahren zur Herstellung von Diarylethanen |
US5756593A (en) | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
DE69626849T2 (de) | 1995-12-22 | 2003-12-24 | Bristol-Myers Squibb Co., Princeton | Verzweigte hydrazongruppen enthaltende kuppler |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
CA2253904A1 (en) | 1996-05-03 | 1997-11-13 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
EP0964702B1 (en) | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
JP4187277B2 (ja) | 1997-04-30 | 2008-11-26 | エンゾン ファーマシューティカルズ, インコーポレイテッド | グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 |
US20040009166A1 (en) | 1997-04-30 | 2004-01-15 | Filpula David R. | Single chain antigen-binding polypeptides for polymer conjugation |
CA2310892A1 (en) | 1997-11-21 | 1999-06-03 | Human Genome Sciences, Inc. | Chemokine alpha-5 |
GB2332539B (en) | 1997-12-17 | 2003-04-23 | Fujitsu Ltd | Memory access methods and devices for use with random access memories |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US7060479B2 (en) | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6214330B1 (en) | 1998-07-13 | 2001-04-10 | Enzon, Inc. | Coumarin and related aromatic-based polymeric prodrugs |
US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
US6323135B1 (en) | 1998-12-09 | 2001-11-27 | Advanced Micro Devices, Inc. | Method of forming reliable capped copper interconnects/with high etch selectivity to capping layer |
JP2000230000A (ja) | 1999-02-08 | 2000-08-22 | Hokkaido Univ | 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体 |
US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US6777387B2 (en) | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
WO2001097855A2 (en) | 2000-06-20 | 2001-12-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
WO2002043771A2 (en) | 2000-12-01 | 2002-06-06 | Cell Works Inc. | Conjugates of glycosylated/galactosylated peptide |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
JP4179771B2 (ja) | 2001-06-25 | 2008-11-12 | 株式会社デンソー | 自動車の乗員保護装置 |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
WO2003040211A2 (en) | 2001-11-07 | 2003-05-15 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
BR0306808A (pt) | 2002-01-09 | 2005-08-30 | Medarex Inc | Anticorpos monoclonais humanos contra cd30 |
EP1585817B1 (en) | 2002-02-20 | 2009-09-02 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
GB0218518D0 (en) | 2002-03-22 | 2002-09-18 | Aventis Pharma Inc | Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
WO2003086312A2 (en) | 2002-04-12 | 2003-10-23 | A & D Bioscience, Inc. | Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof |
US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7413738B2 (en) | 2002-08-13 | 2008-08-19 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on biodegradable linkers |
US7273845B2 (en) | 2002-11-12 | 2007-09-25 | Enzon Pharmaceuticals, Inc. | Polymeric prodrugs of vancomycin |
US7462687B2 (en) | 2002-11-12 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Prodrugs of vancomycin with hydrolysis resistant polymer linkages |
DE10254439A1 (de) | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
US7888536B2 (en) | 2004-02-13 | 2011-02-15 | Quanta Biodesign, Ltd. | Selective and specific preparation of discrete PEG compounds |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
US7595304B2 (en) | 2003-04-13 | 2009-09-29 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
MXPA05012259A (es) | 2003-05-14 | 2006-04-18 | Immunogen Inc | Composicion de farmaco conjugado. |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
SI2489364T1 (sl) | 2003-11-06 | 2015-04-30 | Seattle Genetics, Inc. | Monometilvalinske spojine, konjugirane s protitelesi |
US20060003412A1 (en) | 2003-12-08 | 2006-01-05 | Xencor, Inc. | Protein engineering with analogous contact environments |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
CA2824093C (en) | 2004-03-23 | 2016-10-25 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
EP1747021B1 (en) | 2004-05-19 | 2015-09-09 | E. R. Squibb & Sons, L.L.C. | Self-immolative linkers and drug conjugates |
AU2005332660A1 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
AU2006210837B2 (en) | 2005-01-31 | 2012-07-12 | Genentech, Inc. | Anti-EphB2 antibodies and methods using same |
WO2006088248A1 (ja) | 2005-02-18 | 2006-08-24 | Nof Corporation | ポリオキシアルキレン誘導体 |
US8067546B2 (en) | 2005-04-19 | 2011-11-29 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
US8132476B2 (en) | 2005-06-20 | 2012-03-13 | Hy-Energy, Llc | Method and apparatus for handling small quantities of fluids |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
SI3248613T1 (sl) | 2005-07-18 | 2022-04-29 | Seagen Inc. | Konjugati beta-glukuronidni linker-zdravilo |
US20110014151A1 (en) | 2006-01-11 | 2011-01-20 | Biotech Igg Ab | Macromolecule conjugate |
DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
WO2008025020A2 (en) | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
KR20090057383A (ko) | 2006-09-15 | 2009-06-05 | 엔존 파마슈티컬즈, 인코포레이티드 | 다기능성 링커를 포함하는 표적화된 고분자 전구약물 |
EP2076245A2 (en) | 2006-09-15 | 2009-07-08 | Enzon Pharmaceuticals, Inc. | Lysine-based polymeric linkers |
BRPI0716823A2 (pt) | 2006-09-15 | 2015-05-26 | Enzon Pharmaceuticals Inc | Conjunto poliméricos contendo porções positivamente carregadas |
US8367065B2 (en) | 2006-09-15 | 2013-02-05 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
PT2089425E (pt) | 2006-11-10 | 2011-10-17 | Covx Technologies Ireland Ltd | Compostos anti-angiogénicos |
US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
US7884869B2 (en) | 2007-04-30 | 2011-02-08 | Motorola Mobility, Inc. | Assignment of pixel element exposure times in digital camera modules and mobile communication devices |
JP5690589B2 (ja) | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 親水性スペーサーリンカーを含有する結合体 |
TW200922623A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery systems containing an aromatic allylic acid |
TW200922624A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
US20110263650A1 (en) | 2007-07-20 | 2011-10-27 | Helmholtz-Zentrum Für Infektions-Forschung Gmbh | Tubulysin D Analogues |
CA2695532A1 (en) | 2007-08-20 | 2009-02-26 | Enzon Pharmaceuticals, Inc. | Polymeric linkers containing pyridyl disulfide moieties |
HUE031533T2 (hu) | 2007-10-19 | 2017-07-28 | Seattle Genetics Inc | CD19-kötõszerek valamint alkalmazásuk |
NO2842575T3 (uk) | 2008-03-18 | 2018-02-24 | ||
EP2174947A1 (en) | 2008-09-25 | 2010-04-14 | Universität des Saarlandes | Bioactive pre-tubulysins and use thereof |
WO2010048018A1 (en) | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
WO2010081004A1 (en) | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
ES2464123T3 (es) | 2009-01-12 | 2014-05-30 | University Of Washington | Procedimiento para la 2-sulfatación de glucósidos |
MX368362B (es) | 2009-02-05 | 2019-09-30 | Immunogen Inc | Derivados novedosos de benzodiacepina. |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
WO2011038159A2 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
IN2012DN02780A (uk) | 2009-10-06 | 2015-09-18 | Immunogen Inc | |
US9163060B2 (en) | 2009-11-12 | 2015-10-20 | R&D Biopharmaceuticals Gmbh | Tubulin inhibitors |
EP2322537A1 (en) | 2009-11-12 | 2011-05-18 | R & D Biopharmaceuticals Gmbh | Tubulin inhibitors |
EP2509421B1 (en) | 2009-12-10 | 2020-02-05 | Cedars-Sinai Medical Center | Drug delivery of temozolomide for systemic based treatment of cancer |
KR101510413B1 (ko) | 2010-02-08 | 2015-04-08 | 어젠시스 인코포레이티드 | 161p2f10b 단백질에 결합하는 항체 약물 컨쥬게이트 |
DK2542576T3 (en) | 2010-03-02 | 2016-08-01 | Seattle Genetics Inc | METHODS OF SCREENING ANTIBODIES |
CA2794307A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
WO2011130613A1 (en) | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
WO2011130616A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
WO2011130599A1 (en) | 2010-04-16 | 2011-10-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of adenine nucleoside analogs |
EP2409983A1 (en) | 2010-07-19 | 2012-01-25 | Leibniz-Institut für Pflanzenbiochemie (IPB) | Tubulysin analogues |
BR112013013781A2 (pt) | 2010-12-06 | 2016-09-13 | Seattle Genetics Inc | anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer |
EP3666289A1 (en) | 2011-02-15 | 2020-06-17 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
ES2531471T3 (es) | 2011-02-25 | 2015-03-16 | Lonza Ltd | Enlazador ramificado para conjugados de proteínas-fármacos |
ES2690993T3 (es) | 2011-05-27 | 2018-11-23 | Ambrx, Inc. | Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos |
AU2012301793A1 (en) | 2011-08-30 | 2014-03-20 | Quanta Biodesign, Ltd. | Branched discrette PEG constructs |
EP2751120B1 (en) | 2011-09-20 | 2018-08-22 | MedImmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
EP3388435B1 (en) | 2011-10-14 | 2023-05-03 | Seagen Inc. | Pyrrolobenzodiazepines and targeted conjugates |
JP6273214B2 (ja) | 2012-02-17 | 2018-01-31 | シアトル ジェネティックス, インコーポレイテッド | がんを処置するためのインテグリンαvβ6に対する抗体およびその使用 |
US20130225789A1 (en) | 2012-02-29 | 2013-08-29 | Yi Sun | Polyethylene Glycol Having Hetero Multiple Functional Groups |
EP2850201A4 (en) | 2012-05-11 | 2016-08-31 | Alexander Krantz | Site-specific labeling and targeted administration of proteins for the treatment of cancer |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
CN107982545B (zh) | 2012-05-15 | 2021-04-09 | 联宁(苏州)生物制药有限公司 | 药物偶联物,偶联方法,及其用途 |
JP6423340B2 (ja) | 2012-05-15 | 2018-11-14 | シアトル ジェネティクス,インコーポレイティド | 自己安定化リンカー結合体 |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
US9650331B2 (en) | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
US9872924B2 (en) | 2012-10-19 | 2018-01-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
BR112015008376A2 (pt) | 2012-10-24 | 2017-09-26 | Polytherics Ltd | conjugados fármaco-proteína |
KR102066318B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
AU2014235474B2 (en) | 2013-03-15 | 2017-05-25 | Novartis Ag | Antibody drug conjugates |
US9430462B2 (en) | 2013-07-30 | 2016-08-30 | Edanz Group Ltd. | Guided article authorship |
PL3057585T3 (pl) | 2013-10-15 | 2020-12-28 | Seagen Inc. | Pegylowane elementy lek-łącznik do poprawy farmakokinetyki koniugatu ligand-lek |
KR20220127364A (ko) | 2013-12-19 | 2022-09-19 | 씨젠 인크. | 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커 |
SG10202006504QA (en) | 2014-09-11 | 2020-08-28 | Seattle Genetics Inc | Targeted delivery of tertiary amine-containing drug substances |
GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
MX2017011432A (es) | 2015-03-18 | 2017-11-10 | Seattle Genetics Inc | Anticuerpos contra cumulo de diferenciacion 48 (cd48) y sus conjugados. |
SG11201900699QA (en) | 2016-08-09 | 2019-02-27 | Seattle Genetics Inc | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
MX2019010769A (es) | 2017-03-24 | 2019-12-11 | Seattle Genetics Inc | Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos. |
-
2017
- 2017-03-24 EP EP17771293.2A patent/EP3433278A4/en active Pending
- 2017-03-24 SG SG11201807827VA patent/SG11201807827VA/en unknown
- 2017-03-24 WO PCT/US2017/024148 patent/WO2017165851A1/en active Application Filing
- 2017-03-24 UA UAA201810087A patent/UA125510C2/uk unknown
- 2017-03-24 KR KR1020237031301A patent/KR102626498B1/ko active IP Right Grant
- 2017-03-24 EA EA201892040A patent/EA201892040A1/ru unknown
- 2017-03-24 CN CN201780026818.2A patent/CN109843919A/zh active Pending
- 2017-03-24 MA MA043835A patent/MA43835A/fr unknown
- 2017-03-24 US US16/088,235 patent/US11844839B2/en active Active
- 2017-03-24 CA CA3017527A patent/CA3017527A1/en active Pending
- 2017-03-24 AU AU2017237186A patent/AU2017237186B2/en active Active
- 2017-03-24 BR BR112018069273A patent/BR112018069273A2/pt unknown
- 2017-03-24 KR KR1020187030463A patent/KR20180134351A/ko not_active IP Right Cessation
- 2017-03-24 JP JP2018548056A patent/JP7073266B2/ja active Active
- 2017-03-27 TW TW111150743A patent/TWI839055B/zh active
- 2017-03-27 TW TW106110181A patent/TWI790996B/zh active
-
2018
- 2018-09-13 IL IL261759A patent/IL261759B/en unknown
-
2020
- 2020-03-24 JP JP2020053136A patent/JP2020100669A/ja active Pending
-
2021
- 2021-10-10 IL IL287140A patent/IL287140A/en unknown
-
2022
- 2022-04-08 JP JP2022064462A patent/JP2022082777A/ja active Pending
-
2023
- 2023-06-05 JP JP2023092604A patent/JP2023106627A/ja active Pending
- 2023-09-06 US US18/462,325 patent/US20240197889A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019512492A (ja) | 2019-05-16 |
AU2017237186B2 (en) | 2024-06-20 |
JP2020100669A (ja) | 2020-07-02 |
JP2022082777A (ja) | 2022-06-02 |
KR20230135169A (ko) | 2023-09-22 |
KR20180134351A (ko) | 2018-12-18 |
US20240197889A1 (en) | 2024-06-20 |
WO2017165851A1 (en) | 2017-09-28 |
CN109843919A (zh) | 2019-06-04 |
JP2023106627A (ja) | 2023-08-01 |
TW201735919A (zh) | 2017-10-16 |
EP3433278A4 (en) | 2019-11-06 |
US11844839B2 (en) | 2023-12-19 |
UA125510C2 (uk) | 2022-04-13 |
TW202325718A (zh) | 2023-07-01 |
IL287140A (en) | 2021-12-01 |
IL261759A (en) | 2018-10-31 |
BR112018069273A2 (pt) | 2019-01-22 |
TWI790996B (zh) | 2023-02-01 |
EA201892040A1 (ru) | 2019-04-30 |
CA3017527A1 (en) | 2017-09-28 |
EP3433278A1 (en) | 2019-01-30 |
KR102626498B1 (ko) | 2024-01-19 |
AU2017237186A1 (en) | 2018-11-01 |
US20190388546A1 (en) | 2019-12-26 |
IL261759B (en) | 2021-10-31 |
MA43835A (fr) | 2018-11-28 |
JP7073266B2 (ja) | 2022-05-23 |
TWI839055B (zh) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau |